Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Oral JNJ-41876666 is active against cold allodynia in models of neuropathic pain

Sep. 9, 2010

Rivaroxaban is as effective as standard therapy in treating deep vein thrombosis

Sep. 9, 2010

AZ-004 is efficacious in preclinical model of inflammatory pain

Sep. 9, 2010

BNC-210 is well tolerated in healthy volunteers

Sep. 9, 2010

Ivabradine improves outcome of patients with heart failure in SHIFT trial

Sep. 8, 2010

Italian scientists synthesize new HDAC inhibitor

Sep. 8, 2010

Technetium-99m-labeled MIP-1340 shows suitability for prostate cancer imaging

Sep. 8, 2010

Amantadine and fluoxetine display comparable efficacy in major depressive disorder

Sep. 8, 2010

Prucalopride is safe and efficacious in opioid-induced constipation

Sep. 8, 2010

NC-2500 is selected for clinical development in gout-related hyperuricemia

Sep. 7, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...